...
首页> 外文期刊>Journal of Cancer >The impact of Adult Comorbidity Evaluation-27 on the clinical outcome of elderly nasopharyngeal carcinoma patients treated with chemoradiotherapy or radiotherapy: a matched cohort analysis
【24h】

The impact of Adult Comorbidity Evaluation-27 on the clinical outcome of elderly nasopharyngeal carcinoma patients treated with chemoradiotherapy or radiotherapy: a matched cohort analysis

机译:成人合并症评价-27对化学疗法或放疗治疗的老年鼻咽癌患者临床结果的影响:匹配队列分析

获取原文

摘要

Objectives : To evaluate the prognostic significance of Adult Comorbidity Evaluation-27 (ACE-27) for elderly patients (age ≥70 years) with locoregionally advanced nasopharyngeal carcinoma (NPC) treated with Intensity-Modulated Radiotherapy (IMRT), with or without chemotherapy. Methods : 206 elderly patients with locoregionally advanced NPC treated from December 2006 to December 2016 were involved into analysis as the training cohort. Besides, a separate cohort of 72 patients from the same cancer center collected between January 2003 and October 2006 served as the validation cohort. By using propensity score matching (PSM), we created a balanced cohort by matching patients who received chemoradiotherapy with patients who received IMRT alone. Treatment toxicities were calculated between CRT and RT groups using the χsup2/sup test. The primary endpoint was cancer-specific survival (CSS). Multivariate analysis was performed to assess the relative risk for each factor by using a Cox's proportional hazards regression model. Results : The median follow-up was 39.0 months (range = 3-137 months). In the PSM cohort, patients in the CRT group achieved comparable survival compared with patients in the RT group. The 3-year CSS rate was 64.3% and 65.2%, respectively (P =0.764). In multivariate analysis, the addition of chemotherapy to IMRT was not an independent prognostic factor for CSS, whereas a high ACE-27 score was an independent risk factor. In subgroup analysis with ACE-27 score ≥ 2, the 3-year CSS rate was worse in patients from the CRT group (63.5% vs. 46.3%, P = 0.041). Conclusions : CRT is comparable to IMRT alone for elderly patients with locoregionally advanced NPC. The ACE-27 tool may help to identify high-risk subgroup for poor disease outcome and tailor individualized treatment.
机译:目的:评估成人合并症评价-27(ACE-27)对老年患者(≥70岁)的预后意义,用强度调制放疗(IMRT),有或没有化疗治疗的型脑卒中患者(≥70岁)。方法:206名老年人患有从2006年12月至2016年12月治疗的局部晚期NPC患者参与了分析作为培训队列。此外,2003年1月至2006年1月至2006年1月至2006年10月间收集的同一癌症中心的单独队列的72名患者担任了验证队列。通过使用倾向得分匹配(PSM),我们通过与接受IMRT接受IMRT的患者的患者匹配患者创建了平衡的队列。使用χ 2℃试验在CRT和RT基团之间计算治疗毒性。主要终点是癌症特异性存活率(CSS)。进行多变量分析以评估每种因素的相对风险,通过使用COX的比例危害回归模型。结果:中位后续时间为39.0个月(范围= 3-137个月)。在PSM队列中,与RT组中的患者相比,CRT组的患者达到了可比的存活。 3年的CSS率分别为64.3%和65.2%(P = 0.764)。在多变量分析中,将化学疗法添加到IMRT不是CSS的独立预后因素,而高ACE-27评分是一个独立的危险因素。在ACE-27分数≥2的亚组分析中,CRT组患者的3年CSS率差(63.5%与46.3%,P = 0.041)。结论:CRT与单独的IMRT适用于老年人患有型直接NPC的老年患者。 ACE-27工具可能有助于识别疾病结果差和量身个体化治疗的高危亚组。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号